Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Evelo Biosciences stock | 4.72

Own Evelo Biosciences stock in just a few minutes.

Posted

Fact checked

Evelo Biosciences, Inc is a biotechnology business based in the US. Evelo Biosciences shares (EVLO) are listed on the NASDAQ and all prices are listed in US Dollars. Evelo Biosciences employs 98 staff and has a market cap (total outstanding shares value) of USD$227.5 million.

How to buy shares in Evelo Biosciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Evelo Biosciences. Find the stock by name or ticker symbol: EVLO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Evelo Biosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$4.72, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Evelo Biosciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Evelo Biosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Evelo Biosciences's share price?

Since the stock market crash in March caused by coronavirus, Evelo Biosciences's share price has had significant negative movement.

Its last market close was USD$4.72, which is 19.73% down on its pre-crash value of USD$5.88 and 56.81% up on the lowest point reached during the March crash when the shares fell as low as USD$3.01.

If you had bought USD$1,000 worth of Evelo Biosciences shares at the start of February 2020, those shares would have been worth USD$740.12 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$981.29.

Evelo Biosciences share price

Use our graph to track the performance of EVLO stocks over time.

Evelo Biosciences shares at a glance

Information last updated 2020-10-19.
Latest market close USD$4.72
52-week range USD$3.01 - USD$8.3
50-day moving average USD$4.8943
200-day moving average USD$4.5356
Wall St. target price USD$9.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.27

Buy Evelo Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Evelo Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Evelo Biosciences price performance over time

Historical closes compared with the close of $4.72 from 2020-11-16

1 week (2020-11-20) -1.26%
1 month (2020-10-29) 8.76%
3 months (2020-08-28) 5.83%
6 months (2020-05-29) 8.01%
1 year (2019-11-29) 4.66%
2 years (2018-11-29) -52.32%
3 years (2017-11-26) N/A
5 years (2015-11-26) N/A

Evelo Biosciences financials

Gross profit TTM USD$0
Return on assets TTM -45.64%
Return on equity TTM -103.87%
Profit margin 0%
Book value $1.5
Market capitalisation USD$227.5 million

TTM: trailing 12 months

Shorting Evelo Biosciences shares

There are currently 1.7 million Evelo Biosciences shares held short by investors – that's known as Evelo Biosciences's "short interest". This figure is 19.8% up from 1.4 million last month.

There are a few different ways that this level of interest in shorting Evelo Biosciences shares can be evaluated.

Evelo Biosciences's "short interest ratio" (SIR)

Evelo Biosciences's "short interest ratio" (SIR) is the quantity of Evelo Biosciences shares currently shorted divided by the average quantity of Evelo Biosciences shares traded daily (recently around 139740.20950846). Evelo Biosciences's SIR currently stands at 12.41. In other words for every 100,000 Evelo Biosciences shares traded daily on the market, roughly 12410 shares are currently held short.

However Evelo Biosciences's short interest can also be evaluated against the total number of Evelo Biosciences shares, or, against the total number of tradable Evelo Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Evelo Biosciences's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Evelo Biosciences shares in existence, roughly 40 shares are currently held short) or 0.071% of the tradable shares (for every 100,000 tradable Evelo Biosciences shares, roughly 71 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Evelo Biosciences.

Find out more about how you can short Evelo Biosciences stock.

Evelo Biosciences share dividends

We're not expecting Evelo Biosciences to pay a dividend over the next 12 months.

Evelo Biosciences share price volatility

Over the last 12 months, Evelo Biosciences's shares have ranged in value from as little as $3.01 up to $8.3. A popular way to gauge a stock's volatility is its "beta".

EVLO.US volatility(beta: 0.81)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Evelo Biosciences's is 0.8131. This would suggest that Evelo Biosciences's shares are less volatile than average (for this exchange).

Evelo Biosciences overview

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a monoclonal microbial candidate, which is in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of psoriasis or atopic dermatitis. The company is also developing monoclonal microbial candidates, which are in pre-clinical development stage include EDP1815 for treating psoriatic arthritis, rheumatoid arthritis, and axial spondyloarthritis; EDP1867 for asthma; EDP2939 for inflammatory disease; and EDP1632 for neuro-inflammatory diseases. In addition, it is developing EDP1503, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site